BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Ascletis’ Oral GLP-1 ASC30 Delivers Up to 1.7% HbA1c Reduction in Phase II Diabetes Trial

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. ...

October 30, 2026 | News

Ono Pharma’s ONO-1110 Shows Promising Pain Relief Signals Across Three Phase II Studies

Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...

October 30, 2026 | News

Japan's FY2027 Off-Year Drug Price Revision: 8 Numbers That Decide Who Pays

Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...

October 29, 2026 | Analysis

EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...

October 28, 2026 | News

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

October 27, 2026 | Analysis

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

October 22, 2026 | Analysis

PharmaEssentia Accelerates Global Expansion with US and Japan Drug Approvals and US$46 Million Manufacturing Investment

PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clini...

October 21, 2026 | News

How Long It Takes to Start a Clinical Trial in 8 APAC Markets, Timed

If you are building a 2027 trial budget this month, you are probably working from a spreadsheet with one row per country and a column headed "start-up". Mo...

October 19, 2026 | News

Takeda’s First-in-Class Narcolepsy Drug ORZEYFUL Enters Japan and China Markets Following Regulatory Approvals

ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (...

October 16, 2026 | News

CellFiber Launches Zeito™ Cell Fibre Fabrication Systems in Japan and US to Advance Cell Therapy Manufacturing

CellFiber, a biotechnology company specialising in cell and gene therapy technologies, has announced the official launch of its Zeito™ series of cell...

October 09, 2026 | News

Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand Identity

Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challen...

October 07, 2026 | News

Ractigen Reports First Human Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in hu...

October 05, 2026 | News

Turbine, Daiichi Sankyo Expand Virtual Biology Collaboration to Accelerate ADC Discovery

Turbine, a leading virtual biology company, announced the expansion of its collaboration with Daiichi Sankyo following the successful completio...

September 25, 2026 | News

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanc...

September 25, 2026 | News

Stay Connected